Posaconazole is an orally bioavailable triazole antifungal agent for the treatment and prophylaxis 2 of invasive fungal infection. We evaluated plasma posaconazole concentration data from juvenile 3 (younger than 18 years, n = 12) and adult (18 to 64 years, n = 194) patients who participated in a 4 multicenter, phase 3, open-label study that assessed the efficacy and safety of posaconazole 5 treatment in persons who were intolerant of or had invasive fungal infection refractory to 6 standard antifungal therapies. With the exception of 1 juvenile patient who received 400 mg/day 7 as a divided dose on the day of sample collection, all patients received posaconazole 800 mg/day 8 as an oral suspension in divided doses. Plasma samples were analyzed through a validated liquid 9 chromatographic-tandem mass spectrometric method with a lower limit of quantitation of 1 10 ng/mL. Because plasma posaconazole concentrations are relatively constant at steady state, the 11 average of all plasma concentrations (C av ) for each patient was calculated to provide a single respectively. Overall success rates and adverse event profiles were comparable. In conclusion, 17 posaconazole plasma concentration values were similar in juvenile and adult patients, suggesting 18 that clinical outcomes are expected to be similar in adults and children with refractory invasive 19 fungal infection.
INTRODUCTION 1
idiosyncratic or hypersensitivity reaction to antifungal agents. Patients were considered to have 1 disease refractory to standard therapies (e.g., amphotericin B, other azoles) if they experienced 2 disease progression or if they showed no clinical improvement during antifungal therapy given 3 for an adequate period of time (e.g., 10 to 14 days for cryptococcal meningitis, 7 days for 4 infections caused by Aspergillus spp, 14 days for infections caused by non-Aspergillus moulds, 5 30 days for histoplasmosis, and 180 days of azole therapy for coccidioidomycosis). 6 7 Patients were ineligible for study participation if they had concurrent progressive neurologic 8 disease (e.g., seizures, demyelinating syndromes, unstable multiple sclerosis, peripheral 9 neuropathy), required artificial ventilation and were unlikely to undergo extubation within 24 10 hours of study entry, had a history of serious or severe hypersensitivity to azole antifungals, 11 received medications that are known to interact with azoles and may lead to life-threatening 12 adverse events (i.e., terfenadine, cisapride, ebastine at entry or within 24 hours before therapy, or 13 astemizole at entry or within 10 days of study entry), received drugs that lower azole serum 14 concentrations (eg, rifampin, phenytoin) within 7 days of study entry, had electrocardiography 15 results showing prolonged QTc interval (≥20% above normal) within 7 days of study entry, 16 needed concomitant systemic antifungal agents during the study period, had significantly 17 abnormal hepatic function test results (alanine aminotransferase or aspartate aminotransferase 18 >10 times the ULN), or were expected to survive less than 72 hours. Women were excluded from 19 participation if they were pregnant or lactating, were using inadequate contraception, or had not 20 undergone surgical sterilization. 21 
22

A C C E P T E D
on
Pharmacokinetic analysis 6
Blood samples (6 mL) for determining posaconazole concentrations in juvenile patients 13 years 7 of age or older were to be collected before and after the first daily dose, at approximately 0, 2, 4, 8 and 6 hours at week 2 and approximately 30 minutes before the first daily dose and along with 9 the adult patients at 2 to 4 hours after that dose at week 16. However, the blood collection 10 schedule for the juvenile population could not be strictly followed. On a given day, 2 to 6 11 samples were taken from 11 patients, and from 1 patient a single sample was collected. 12 
13
Plasma was separated via centrifugation and stored frozen at -20˚C until it could be analyzed. To 14 determine posaconazole concentrations, plasma samples were analyzed using a positive-ion 15 Turbo IonSpray (PE Applied Biosystems, Foster City, CA) liquid chromatographic-tandem mass 16 spectrometric (LC-MS-MS) method. The calibration range was 1.00 to 4,000 ng/mL. 17
18
Between-run accuracy (percentage difference from actual value) values of the quality control 19 (QC) for lower limit of quantitation (LLOQ; 1.00 ng/mL), low (3.00 ng/mL), medium (1,500 20 ng/mL), and high (3,000 ng/mL) QC samples were -7.59, -1.31, -0.504, and -3.71, respectively. 21
Between-run precision (percentage coefficient of variation) values of the QC samples at LLOQ, 22 low, medium, and high concentrations were 15.7, 9.49, 7.07, and 8.54, respectively. 23 1 Because posaconazole is slowly eliminated and has a long terminal phase half life (t 1/2 ) of 35 2 hours, a twice-daily or four times daily dosing regimen provides plasma concentrations that are 3 relatively flat and unchanged over time at steady state. Thus, the average of all the plasma 4 concentrations (C av ) in a patient was calculated to provide a single steady state plasma 5 posaconazole concentration for each patient. Descriptive statistics (mean, median, standard 6 deviation, minimum, and maximum) using each patient's C av values were then calculated by age 7 group. Juvenile pharmacokinetic data (composite plasma concentration-time plots and C av ) were 8 compared with data from adult patients. 9
Data review committee 11
A blinded data-review committee (DRC) composed of 17 experts in the diagnosis and treatment 12 (n = 15) or in the radiographic analysis of invasive fungal infections (n = 2) reviewed each case 13 to ensure that all patients met predetermined eligibility criteria. Teams of 2 or 3 DRC members 14 determined eligibility and outcomes using predefined criteria. The DRC reviewed treatment 15 outcomes at month 1, month 3, month 6 and at the end of therapy (or at 12 months if treatment 16 went beyond that time). 17
18
Efficacy definitions 19
Successful outcome was defined as the resolution of all attributable symptoms, signs, and 20 radiographic abnormalities (complete response) or as clinically meaningful improvement in 21 attributable symptoms, signs, and radiographic abnormalities (partial response). Nonsuccessful 22 outcome was defined as no improvement in attributable symptoms, signs, and radiographic 23 abnormalities (stable disease) or deterioration in attributable clinical or radiographic 1 abnormalities that necessitated alternative antifungal therapy or resulted in death (treatment 2 failure). If for any reason the response could not be assessed, the patient was considered to have 3 had a nonsuccessful outcome. 4 
5
Safety analysis 6
Reported adverse events (spontaneously reported, solicited via generalized questioning, or 7 identified during routine laboratory testing or physical examination), clinical laboratory test 8 results, measurements of vital signs, and electrocardiograms were used to assess safety (24) . 9
Investigators determined whether each adverse event was unlikely, possibly, or probably related 10 to posaconazole treatment. A treatment-related adverse event was defined as any event the 11 investigator considered to be at least possibly related to posaconazole treatment or for which the 12 investigator did not assign a relationship (i.e., any adverse event not specifically considered to be 13 unlikely related to treatment). 14 15
RESULTS
16
Patient demographics 17
Of the 12 juvenile patients evaluated, 7 were boys and 5 were girls. Baseline age and body 18 weight ranged from 8 to 17 years and from 24 to 76 kg, respectively (Table 1) Eleven juvenile patients received a maintenance dose of 800 mg/day posaconazole oral 5 suspension in divided doses. One patient (patient #1) received 400 mg/day posaconazole in 6 divided doses on the day of sample collection and 800 mg/day in divided doses before the day of 7 sample collection. Adult patients received posaconazole 800 mg/day in divided doses. 8 9
All infections 10
Posaconazole C av values in juvenile and adult patients were comparable. Mean posaconazole C av 11 values were 776 ng/mL in juvenile patients and 817 ng/mL in adult patients (Table 2) . Maximum 12 posaconazole C av values were 2,891 ng/mL and 3,710 ng/mL, respectively. Minimum 13 posaconazole C av values in juveniles and adults were 85.3 ng/mL and 0 ng/mL, respectively. 14 Individual C av values for juvenile patients are shown in Table 3 between the adult and juvenile groups, indicating that the C av values in these 2 age groups were 18 similar (Fig. 3) . However, because of the disparity between the juvenile and adult sample sizes, 19 definitive conclusions cannot be made. Interpatient variability of posaconazole plasma 20 concentration has been noted in both patient populations. As shown in Fig. 4A -C, no association 21 was apparent between age, body weight, or body surface area and posaconazole C av (R 2 = 0.06, 22 1 Aspergillus infections 2 Plasma posaconazole concentrations were also analyzed for the subset of patients who had Aspergillus 3 infections (patients #s 1, 3, 5, 10, and 11) because these were the most common fungal infections 4 observed in the present study and are the most frequently treated fungal infection in clinical practice. 5
Although the pharmacokinetic data in the juvenile population were drawn from a small sample size (n 6 = 5), the pharmacokinetic parameters were comparable to those of adults. Mean plasma posaconazole 7
C av values were 1,058 ng/mL in juvenile patients and 684 ng/mL in adult patients (Table 2) . Maximum 8 plasma posaconazole C av values were 2,891 ng/mL and 3,340 ng/mL in juvenile and adult patients, 9
respectively. Minimum posaconazole C av values in juveniles and adults were 85.3 ng/mL and 32.5 10 ng/mL, respectively. 11
12
Clinical efficacy in the juvenile population 13 Eight patients were included in the MITT group. Six patients had disease that was considered 14 refractory to available antifungal therapy, 1 was considered intolerant of available antifungal 15 therapy, and 1 was considered both refractory and intolerant. (Table  5 3). In addition, 2 patients experienced renal insufficiency (possibly related to study treatment). In 6 this small series of patients, there was no clear relationship between the duration of posaconazole 7 exposure and the emergence of treatment-related adverse events. 8 9 Overall, the treatment-related adverse events were similar among juvenile and adult patients and 10 consistent with a profoundly immunocompromised patient population with severe underlying 11 disease. In the juvenile population, 3 of 7 (43%) treatment-related adverse events were 12 gastrointestinal. The most common (≥5%) treatment-related adverse events in the overall 13 population (adult and juvenile) were nausea (9%), vomiting (6%), abdominal pain (5%), and 14 headache (5%) (24) . (29) 12 have been published. Two studies (12, 25) with itraconazole show similar peak and trough 13 concentrations in pediatric and adult patients (17 patients, ages 2 to 18 years), and another (7) 14 reports pediatric concentrations that were approximately one third of those attained by adults (26 15 patients, ages 6 months to 12 years) (4, 7, 22, 23) . The difference between pediatric and adult 16 patients may result in part from greater itraconazole clearance in younger children (25). 17
Fluconazole has an age-dependent volume of distribution that is greatest in neonates and 18 decreases by young adulthood to values approaching those in adults (562 patients, ages 0 to 17) 19 (3, 17) . Compared with adults, fluconazole is eliminated much more slowly in neonates and 20 premature infants and more rapidly in other pediatric patients (3, 17). Voriconazole is eliminated 21 more rapidly in pediatric patients than it is in adult patients (35 patients, ages 2 to 11) (29). 22
In these studies, the safety profiles of itraconazole, fluconazole, and voriconazole were similar in 1 adult and pediatric patients. In both adults and children, the adverse events most frequently 2 reported with itraconazole (7, 12) and fluconazole (17) were gastrointestinal. Transient visual 3 disturbances were the most common adverse events associated with voriconazole in children and 4 in adults (29). 5 6 Our investigation focused on plasma posaconazole concentrations at an early stage of the drug 7 development program and did not seek to provide exhaustive comparative data on the 8 pharmacokinetics of posaconazole in juvenile and adult patients. In addition, the ITT population 9 on which our analysis is based was limited to 12 juvenile patients, compared with 194 adults. 10 Furthermore, the blood collection schedule for the juvenile population could not be strictly 11 followed during the trial. However, limited plasma concentration data in juvenile patients did 12 reveal a relatively flat steady state profile consistent with a long terminal phase half-life, as in 13 adults. Although data are limited, a lack of association was apparent between posaconazole 14 plasma C av and age, body weight, or body surface area. Posaconazole C av values in the youngest 15 (8-year-old) patient (227 ng/mL) and oldest (17-year-old) subject (238 ng/mL) were similar. It 16 is noteworthy that some protocol deviations also occurred in juvenile studies with fluconazole; 17 these deviations resulted from the clinical condition of the patients and from the priority given to 18 their well-being rather than to the pharmacokinetic objectives of the studies (3). 
